However, promising anti-tumor activity was reported with the combination of tiragolumab and atezolizumab in the GO30103 study, with a confirmed objective response rate of 46% in the subset of patients with PD-L1-positive NSCLC [13]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.